Compare Amphastar Pharmaceuticals Inc (AMPH) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs The Coca-Cola Co K — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while The Coca-Cola Co K trades at $86.52 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 432.6× Amphastar Pharmaceuticals Inc's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | KO | |
|---|---|---|
Market Cap | $863.95M | $373.76B |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $89.08 |
52-Week Low | $16.87 | $65.67 |
Enterprise Value | $1.26B | $400.93B |
Volume | — | 14,630,257 |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Coca-Cola (KO) trades at $86.51, down 0.62% on the day, with a bullish technical outlook supported by moving averages and key indicators like RSI at 69.16. The company shows strong fundamentals with a 27.33% net margin in 2025 and consistent earnings beats, alongside a robust dividend history of 64 consecutive annual increases. Recent news highlights institutional buying and stable demand trends, per Bank of America on April 10, 2026.
The stock presents a favorable investment case with a consensus price target of $95.83, implying ~11% upside, backed by analyst buy ratings at 60.4%. Risks include rising debt levels and regional demand volatility, but KO's global brand and profitability support long-term value for dividend-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
